The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

A novel combination for relapsed/refractory multiple myeloma ... Staging System III myeloma, six of eight with high-risk cytogenetics, and 11 of 18 with extramedullary disease.

This approach could be an important consideration in the management of heavily pretreated patients with chemorefractory multiple myeloma, even at the stage of terminal illness with extramedullary ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...